Following 110 years of neglect, an official day for Chagas disease is declared

Geneva, Switzerland – 24 May 2019
The delegates at the World Health Assembly (WHA) have today approved the creation of a World Chagas Day. People affected by Chagas worldwide celebrate this important step in fighting for recognition of this neglected disease.
The International Federation of People Affected by Chagas Disease (FINDECHAGAS) today celebrates the creation of the World Day of People Affected by Chagas at the 72nd World Health Assembly (WHA) in Geneva, Switzerland.

DNDi and Atomwise collaborate to advance drug development using AI for neglected diseases

Geneva, Switzerland and San Francisco, USA – 16 April 2019
Efforts to discover novel compounds against Chagas disease see early successes – part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards program to fast track drug development
Atomwise, Inc., a biotech company using artificial intelligence (AI) for drug discovery, and DNDi, a not-for-profit research and development organization working to deliver new treatments for neglected diseases, today announced that promising drug-like compounds have been discovered in a programme to develop first-in-class treatments for Chagas disease. The research collaboration is part of Atomwise’s Artificial Intelligence Molecular Screen (AIMS) Awards programme.

Chagas disease: the time is now to end 110 years of neglect

Rio de Janeiro – 11 April 2019
The people affected by Chagas disease will claim this 14th of April as World Chagas Day in the hope of increasing global awareness, building on the progress already made against this disease, which has been neglected for more than a century
The International Federation of Associations of People Affected by Chagas disease (FINDECHAGAS) has launched an online petition through the platform change.org in support of the official declaration of April 14th as their World Day. This proposal will be tabled at the 72nd World Health Assembly, to be held in Geneva at the end of May 2019. The particular date has been chosen because on that same day, 110 years ago, the Brazilian doctor Carlos Chagas confirmed the first case of the disease in a child, called Berenice Soares.

GARDP set up as independent legal entity

Geneva, Switzerland – 2 April 2019
Continued close collaboration with founding partners will strengthen GARDP’s efforts to address AMR
GARDP is now an independent legal entity following a successful three-year incubation, hosted by DNDi. During this time, GARDP has already begun working with partners to develop antibiotics to tackle drug-resistant infections which pose a threat to global health and development, including the achievement of the Sustainable Development Goals.

Study shows dramatically shorter treatment for Chagas disease could be just as effective, and significantly safer

Barcelona/Rio de Janeiro – 14 March 2019
Results could help remove one of the barriers to treatment scale up and bring new hope for people with Chagas disease
A two-week treatment course for adult patients with chronic Chagas disease showed, when compared to placebo, similar efficacy and significantly fewer side effects than the standard treatment duration of eight weeks, according to the results of a clinical trial in Bolivia led by DNDi.

Wellcome commits £10 million to DNDi to develop new generation of oral drugs to treat leishmaniasis

London/Geneva – 5 February 2019
Wellcome has committed over £10 million to DNDi to develop new treatments for leishmaniasis, one of the world’s most devastating parasitic diseases. The three-year partnership will enable DNDi and Wellcome to develop new combinations of entirely new, all-orally acting chemical entities, through a joint strategy that also harnesses the strengths of the pharmaceutical and biotechnology industries, academia, and product development partnerships.

Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo

Paris/Geneva – 30 January 2019
Marketing authorization of fexinidazole for the treatment of Trypanosoma brucei gambiense human African trypanosomiasis, more commonly known as sleeping sickness, has been granted in the Democratic Republic of Congo (DRC). This approval paves the way for the distribution of fexinidazole in endemic countries this year, with another submission planned in Uganda.

Drugs for Neglected Diseases initiative and The BMJ launch a special collection on neglected diseases and innovation in South Asia

New Delhi- 23 January 2019
Research and policy Innovation is vital for sustained control & elimination of neglected diseases in South Asia
DNDi has launched a special collection of articles entitles ‘Neglected Diseases and Innovation in South Asia’ published today by The BMJ. The collection brings together over 30 authors from across South Asia and internationally, to identify research priorities and recommendations for action to improve the health of neglected patients in the region. The collection maps progress in the control or elimination of neglected diseases such as lymphatic filariasis, kala-azar, and snakebites in the region, and highlights the growing challenge of antimicrobial resistance.

Combination therapy found to be more effective in treating patients with leishmaniasis and HIV

Geneva/Nairobi – 17 January 2019
The results of clinical trials conducted in Ethiopia by DNDi, in partnership with Médecins Sans Frontières, the University of Gondar, and Addis Ababa University, open the way for more effective and safer treatments for people with both HIV and visceral leishmaniasis, a group of patients who have historically suffered from poor treatment options. The results were published today in PLOS Neglected Tropical Diseases.

European Medicines Agency recommends fexinidazole, the first all-oral treatment for sleeping sickness

Paris/Geneva – 16 November 2018

  • The positive opinion is the result of a 10-year partnership between the Drugs for Neglected Diseases initiative (DNDi), Sanofi, and African partners
  • Fexinidazole will support international efforts to eliminate sleeping sickness, a fatal neglected tropical disease endemic to Africa

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive scientific opinion of fexinidazole, the first all-oral treatment that has been shown to be efficacious for both stages of sleeping sickness. This approval is a result of clinical trials led by the non-profit research and development organization DNDi and an application submitted by Sanofi. The decision paves the way for the distribution of fexinidazole in endemic countries in 2019.

New hope for PKDL patients in Africa as clinical trial aims to make treatment safer and easier

Nairobi/Khartoum – 12 September 2018
Trial to take place in Sudan, which has the world’s highest rates of this highly stigmatizing disease
A clinical trial to find a better treatment for severe or chronic cases of post kala-azar dermal leishmaniasis (PKDL) in Africa has begun in Dooka, Sudan. The objective of this clinical trial, which is being conducted by the DNDand the Institute for Endemic Diseases at the University of Khartoum, is to shorten the length of hospitalization for PKDL, and deliver a treatment that is safer to use and easier to administer.

FIND and DNDi team up to support Malaysian MOH efforts to simplify and decentralize hepatitis C screening & treatment

Amsterdam/Geneva – 23 July 2018
Initiative in Malaysia to enhance country’s public health approach to hepatitis C
FIND and the DNDi will partner to generate evidence that will support policy change and scale up of hepatitis C diagnosis and treatment. This work, announced at the AIDS 2018 conference in Amsterdam and ahead of World Hepatitis Day 2018, is being conducted in collaboration with the Ministry of Health in Malaysia with a view to overcoming barriers to diagnosis and treatment.

DNDi agreement with Colombia Ministry of Health and Social Welfare to guarantee access to comprehensive care for Chagas patients

Bogotá, Colombia – 14 April 2018
Objective is to improve access to diagnosis and treatment of people affected by this disease
An agreement to facilitate and strengthen access to diagnosis and treatment of patients with Chagas and other diseases of public health interest has been signed by the Colombian Ministry of Health and Social Protection and the non-profit research and development organization Drugs for Neglected Diseases initiative (DNDi).

Drug approved in Argentina for treatment of Chagas disease in children

Buenos Aires, Argentina – 13 April 2018
Argentina has approved the paediatric indication of a drug used for treatment of Chagas disease, benznidazole, which will now be available in 12.5 mg pills, the dose required to treat children under the age of 2. The indication was approved by the Argentinian National Administration for Drugs, Food, and Medical Technologies (ANMAT).

Clinical trial to find new treatment for visceral leishmaniasis begins in eastern Africa

Addis Ababa – 13 April 2018
Study launched as part of new Afri-KA-DIA Consortium will also assess diagnostic tools
A new study to find a safer, efficacious and more patient-friendly treatment and improved diagnostic tools for people living with visceral leishmaniasis (VL) has begun in eastern Africa, within the new Afri-KA-DIA consortium with funding from The European & Developing Countries Clinical Trials Partnership (EDCTP). The large-scale Phase III clinical trial seeks to assess the efficacy and safety of a combination of miltefosine and paromomycin in treating VL in eastern Africa.

New affordable hepatitis C combination treatment shows 97% cure rate

Paris – 12 April 2018
Results support a public health approach to hepatitis C
An affordable hepatitis C combination treatment including the new drug candidate ravidasvir has been shown to be safe and effective, with extremely high cure rates for patients, including hard-to-treat cases, according to interim results from the Phase II/III STORM-C-1 trial presented by the non-profit research and development organisation Drugs for Neglected Diseases initiative (DNDi) at the International Liver Conference in Paris.

Takeda Pharmaceutical and DNDi collaborate to progress a potential new drug for visceral leishmaniasis through the R&D pipeline

Osaka, Japan and Geneva, Switzerland – 5 April 2018
Efforts funded by the Global Health Innovative Technology Fund for pre-clinical and phase I clinical studies
Takeda Pharmaceutical Co., Ltd. and DNDtoday announced that they have signed an agreement to collaborate in conducting preclinical and phase I clinical studies on drug candidate compounds that had been discovered among the aminopyrazole compound class, aimed at developing an innovative drug for the treatment of visceral leishmaniasis (VL).
[Japanese]

DNDi, GlaxoSmithKline, and University of Dundee to identify drug candidates to treat leishmaniasis and Chagas disease

Geneva / Brentford / Dundee – 27 March 2018
The not-for-profit research and development organization Drugs for Neglected Diseases initiative (DNDi) will collaborate with GlaxoSmithKline (GSK), and the University of Dundee Drug Discovery Unit (DDU), in a bid to discover new pre-clinical drug candidates targeting two parasitic neglected tropical diseases (NTDs), leishmaniasis and Chagas disease.